Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast for nummular eczema
2016-002351-16Phase 2Terminated
- Sponsor
- Technical University of Munich Faculty of Medicine
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in discoid eczema comparing Apremilast with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Dec 2016; status: terminated.
02
Drugs
apremilast
03
Conditions
discoid eczema
Beyond the preview
Go deeper on 2016-002351-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002351-16.